<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000664</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 141</org_study_id>
    <secondary_id>CS-PG89-36</secondary_id>
    <secondary_id>FDA 70A</secondary_id>
    <nct_id>NCT00000664</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals</brief_title>
  <official_title>Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety of polyethylene glycolated IL-2 (PEG IL2) administered weekly or&#xD;
      biweekly (per amendment) in a setting of oral zidovudine (AZT). To determine the effect of&#xD;
      PEG IL2 in combination with AZT on parameters assessing the immune system as well as HIV&#xD;
      virus and antibody titers. To evaluate a chronic dosing study phase offered to patients who&#xD;
      complete the initial 25-week regimen.&#xD;
&#xD;
      Recent research has focused on enhancing cell-mediated immunity and reducing or eliminating&#xD;
      viral replication (reproduction and growth). A main thrust of current treatment is the&#xD;
      combination of antiviral drugs that may be more effective when combined than when each is&#xD;
      used alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent research has focused on enhancing cell-mediated immunity and reducing or eliminating&#xD;
      viral replication (reproduction and growth). A main thrust of current treatment is the&#xD;
      combination of antiviral drugs that may be more effective when combined than when each is&#xD;
      used alone.&#xD;
&#xD;
      Four groups are studied for a period of at least 25 weeks. Patients are observed for a&#xD;
      minimum of 6 hours after infusion of PEG IL2. The 4 groups of patients are: Group A -&#xD;
      asymptomatic with T4 count &gt; 400 cells/mm3 (7 patients); Group B - asymptomatic with T4 count&#xD;
      between 200 and 400 cells/mm3 (7 patients); Group C - asymptomatic with T4 count &lt; 200&#xD;
      cells/mm3 (5 patients); Group D - diagnosed as having AIDS related complex (ARC) or AIDS (7&#xD;
      patients). All patients receive AZT. After a minimum 2-week period of AZT, patients receive&#xD;
      an infusion of PEG IL-2 at 3 consecutive weekly intervals, followed by a 3-week period of AZT&#xD;
      alone. This cycle (3 weeks of AZT and PEG IL-2 followed by 3 weeks of AZT alone) is repeated&#xD;
      a total of three times (for a total of 18 weeks) followed by 8 weeks of AZT alone.&#xD;
&#xD;
      PER AMENDMENT: Ten patients may qualify for one of two groups: Group 1 - T4 count 200 - 400&#xD;
      cells/mm3 and meet all criteria established for Group B of the original protocol; Group 2 -&#xD;
      T4 count &lt; 200 cells/mm3 and meet all criteria established for Groups C and D of original&#xD;
      protocol. Patients will receive an amended schedule of PEG IL2 IV every other week for eight&#xD;
      doses, with dose escalation every other week for eight weeks permitted only in Group 2&#xD;
      patients who failed to show a 20 percent rise in T4 count at week 9 and who suffered no CNS&#xD;
      or other adverse events at the lower dose.&#xD;
&#xD;
      PER ADDITIONAL AMENDMENT: Up to 10 additional patients may be treated at each dose of PEG IL2&#xD;
      on the biweekly schedule. Patients who respond to treatment on the biweekly schedule are&#xD;
      eligible for an additional 9 weeks at their current dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>26</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2, Polyethylene Glycolated</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylactic pentamidine for Pneumocystis carinii pneumonia (PCP).&#xD;
&#xD;
          -  Topical steroids.&#xD;
&#xD;
        Patients must:&#xD;
&#xD;
          -  Be HIV positive. Fit one of the zidovudine use groups listed in Disease Status. Be&#xD;
             able to give informed consent.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Basal cell carcinoma of the skin, in situ carcinoma of the cervix, Kaposi's sarcoma.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Major organ allograft.&#xD;
&#xD;
          -  Significant cardiac disease or central nervous system lesions.&#xD;
&#xD;
          -  Known previous intolerance to zidovudine (AZT) at 500 mg/day.&#xD;
&#xD;
          -  Active opportunistic infections. Score of &gt; 0.5 on the ACTG AIDS dementia complex&#xD;
             staging test. Any focal abnormality on neurologic exam.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Chemotherapy, hormonal therapy, or other immunotherapy.&#xD;
&#xD;
          -  Other investigational drugs, agents, or devices.&#xD;
&#xD;
          -  Beta-blockers.&#xD;
&#xD;
          -  Steroids other than topical.&#xD;
&#xD;
          -  Antihypertensive medication other than diuretics.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of seizures. Concurrent neoplasms not specifically allowed.&#xD;
&#xD;
          -  Concomitant conditions listed in Exclusion Co-existing Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Anti-HIV medication other than zidovudine (AZT).&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Systemic steroids.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Interleukins.&#xD;
&#xD;
          -  Other chemotherapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Groups B, C, D&#xD;
&#xD;
          -  Transfusions.&#xD;
&#xD;
        Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TC Merigan</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>J Korvick</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis. 1993 Mar;167(3):519-25. doi: 10.1093/infdis/167.3.519.</citation>
    <PMID>8095058</PMID>
  </reference>
  <verification_date>December 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2008</last_update_posted>
  <keyword>Polyethylene Glycols</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

